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Recent clinical trials have shown highly promising
responses in a subset of patients treated with immune
checkpoint inhibitory anti-programmed cell death-1,
anti-programmed cell death ligand-1 (PD-1), and anti-
cytotoxic T-lymphocyte-associated antigen-4 antibodies
(CTLA-4) [1-4]. However, immunotherapy against
poorly immunogenic cancers remains a challenge. Large,
modestly immunogenic CT26 tumors or poorly immu-
nogenic metastatic 4T1 tumors in mice were unrespon-
sive to anti-PD-1 and anti-CTLA-4 treatments. Co-
treatment with DNA methyltransferase and HDAC inhi-
bitors, and checkpoint inhibitors markedly improved
treatment outcomes, curing more than 80% of the
tumor-bearing mice. Functional studies revealed that the
primary targets of the epigenetic modulators were mye-
loid-derived suppressor cells (MDSCs). In addition,
reduction of MDSCs using antibodies directed against
them or a PI3K inhibitor that reduced circulating
MDSCs had similar antitumor effects to those observed
with the epigenetic modulators. Our results show that
elevated myeloid-derived suppressor cells (MDSCs) are
responsible for the resistance to checkpoint inhibitors
and that elimination of MDSCs can lead to cures of
experimental, metastatic tumors.
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